EGR1 functions as a new host restriction factor for SARS-CoV-2 to inhibit virus replication through the E3 ubiquitin ligase MARCH8

J Virol. 2023 Oct 31;97(10):e0102823. doi: 10.1128/jvi.01028-23. Epub 2023 Sep 29.

Abstract

Emerging vaccine-breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants highlight an urgent need for novel antiviral therapies. Understanding the pathogenesis of coronaviruses is critical for developing antiviral drugs. Here, we demonstrate that the SARS-CoV-2 N protein suppresses interferon (IFN) responses by reducing early growth response gene-1 (EGR1) expression. The overexpression of EGR1 inhibits SARS-CoV-2 replication by promoting IFN-regulated antiviral protein expression, which interacts with and degrades SARS-CoV-2 N protein via the E3 ubiquitin ligase MARCH8 and the cargo receptor NDP52. The MARCH8 mutants without ubiquitin ligase activity are no longer able to degrade SARS-CoV-2 N proteins, indicating that MARCH8 degrades SARS-CoV-2 N proteins dependent on its ubiquitin ligase activity. This study found a novel immune evasion mechanism of SARS-CoV-2 utilized by the N protein, which is helpful for understanding the pathogenesis of SARS-CoV-2 and guiding the design of new prevention strategies against the emerging coronaviruses.

Keywords: EGR1; IFN-regulated antiviral protein; MARCH8; SARS-CoV-2; interferon; nucleocapsid protein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 / virology
  • Drug Discovery
  • Early Growth Response Protein 1* / metabolism
  • Host Microbial Interactions*
  • Humans
  • SARS-CoV-2* / growth & development
  • SARS-CoV-2* / pathogenicity
  • Ubiquitin-Protein Ligases* / metabolism
  • Ubiquitins / metabolism
  • Virus Replication*

Substances

  • CALCOCO2 protein, human
  • Early Growth Response Protein 1
  • EGR1 protein, human
  • MARCHF8 protein, human
  • nucleocapsid phosphoprotein, SARS-CoV-2
  • Ubiquitin-Protein Ligases
  • Ubiquitins